MinervaX announces positive results from Phase I trial in 240 healthy adult women with its innovative Group B Streptococcal (GBS) vaccine to prevent life-threatening infections in newborns.
- MinervaX announces completion of 47.4 mEUR financing 15/12/2020
- MinervaX announces investment of 4.4 mEUR 21/01/2019
- MinervaX announces results from Phase I clinical trial 05/01/2017
- Innovation Foundation Grant 19/09/2016
- Primary Endpoint Data from Phase I Part B 31/08/2016